---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-017913"
form_type: "8-K"
ticker: "SSKN"
cik: "0001051514"
company_name: "STRATA Skin Sciences, Inc."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T02:54:32.800175+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# STRATA Skin pre-announces Q1 2023 revenue $7.3-$7.8M, best Q1 since 2016

## Summary
- Preliminary Q1 2023 revenue $7.3-$7.8 million, strongest first quarter since 2016.
- Placed 44 TheraClear X devices in Q1; over 3,000 treatments sold since Jan 2023 launch.
- Converted 86 Pharos accounts to XTRAC devices from RaMedical acquisition.
- CEO Bob Moccia cites strong sales momentum and expects meaningful revenue impact in 2023.

## SEC filing metadata
- accession: 0001140361-23-017913
- form_type: 8-K
- ticker: SSKN
- cik: 0001051514
- company_name: STRATA Skin Sciences, Inc.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1051514/000114036123017913/0001140361-23-017913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1051514/000114036123017913/brhc20051325_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-017913
- JSON: https://secwatch.observer/filing/0001140361-23-017913.json
- Plain text: https://secwatch.observer/filing/0001140361-23-017913.txt

## Key facts
- Earnings Releases
  STRATA Skin Sciences, Inc. reported first fiscal quarter of 2023 results: revenue range of $7.3 - $7.8 million.
  - Period: first fiscal quarter of 2023
  - Revenue: range of $7.3 - $7.8 million
  - Result: preliminary results
  source text: --- EX-99.1 2 brhc20051325_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STRATA Skin Sciences Pre-Announces First Quarter 2023 Results • Preliminary revenue to be within the range of $7.3 - $7.8 million and expected to be the strongest first-quarter results since first quarter of 2016 • Company exceeds plan with 44 TheraClear ® X placements in the first quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1051514/000114036123017913/0001140361-23-017913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.